Latest news
Trevi Therapeutics (TRVI) Starts Key Cough Trials, Is It Still 29% Below Fair Value? - SahmSahm · Sat, 08 Aug 2026 19:09:24 GMTTrevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates - MarketBeatMarketBeat · Fri, 07 Aug 2026 23:12:38 GMTTREVI (BIT:TFIN) Stock Rebounds On Profit Jump As Valuation Stays Rich - simplywall.stsimplywall.st · Fri, 07 Aug 2026 19:57:33 GMTTrevi Therapeutics Q2 Earnings Call Highlights - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 18:04:23 GMTTrevi Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.17, Implies 58% Upside - TradingViewTradingView · Fri, 07 Aug 2026 17:20:32 GMTOppenheimer Adjusts Trevi Therapeutics PT to $25 From $24, Maintains Outperform Rating - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 13:52:56 GMTTREVI THERAPEUTICS, INC. : OPPENHEIMER RAISES TARGET PRICE TO $25 FROM $24 - BitgetBitget · Fri, 07 Aug 2026 13:03:32 GMTCantor Fitzgerald Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock - MarketBeatMarketBeat · Fri, 07 Aug 2026 12:42:43 GMT